Sayed Mehdi Hamadani, MD, Hematology, Milwaukee, WI, Froedtert and the Medical College of Wisconsin Froedtert Hospital

Sayed MehdiHussainHamadaniMD

HematologyMilwaukee, WI

Physician

Dr. Hamadani is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hamadani's full profile

Already have an account?

  • Office

    9200 W Wisconsin Ave
    Division Of Neoplastic Diseases
    Milwaukee, WI 53226
    Phone(414) 805-6800
    Fax(414) 805-6805
  • Is this information wrong?

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship
  • University of Oklahoma Health Sciences Center
    University of Oklahoma Health Sciences CenterResidency
  • King Edward Medical University
    King Edward Medical UniversityMedicalSchool

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2013 - 2021
  • WV State Medical License
    WV State Medical License Active through 2014
  • American Board of Internal Medicine Hematology

Publications & Presentations

PubMed

Abstracts/Posters

  • Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
    Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
    Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
    Mehdi Hamadani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lym... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations